5^th World Congress on Cell & Stem Cell Research March 23-25, 2015 Chicago, Illinois, USA

James Sherley, graduated from Harvard College (1980) and completed joint M.D./Ph.D. Degrees at the Johns Hopkins University School of Medicine (1988). After post-doctoral studies at Princeton University, beginning in 1991 he started the cancer cell molecular biology research at Fox Chase Cancer Center. In 1998, he began adult stem cell research at Massachusetts Institute of Technology, and in 2007 continued at Boston Biomedical Research Institute. In 2013, he founded the Adult Stem Cell Technology Center, LLC, (ASCTC), which he currently directs. ASCTC is developing technologies for mass-producing human tissue stem cells for applications in drug development and transplantation medicine. Honors & Awards 2006 NIH Director's Pioneer Award 2003 Ellison Medical Foundation Senior Scholar Award in Aging Research 1993 Pew Scholar Award in the Biomedical Sciences

Adult stem cells, adult stem cell expansion, adult stem cell-specific biomarkers, adult stem cell quantification, induced pluripotent stem cell production efficiency, cancer, aging, drug development, immortal DNA strands, non-random segregation, H2A.Z, epigenomics, epigenetics.

Drapeau holds a Bachelor’s degree in Honors Neurophysiology and a Master’s degree in Neurology and Neurosurgery from Canada’s McGill University in Montreal, Quebec, with work performed at the Montreal Neurological Institute. His thesis was on epileptogenesis and the role of eicosanoids in long-term potentiation and he completed further scientific training in variable projection microscopy at Bradford Research Institute and in ion-selective microelectrode recordings at St-Anne Hospital in France. Mr. Drapeau has been the Director of Research and Development at Cell Tech International and then Desert Lake Technologies, before co-founding STEMTech HealthSciences and becoming its Chief Science Officer. He is the author of the Stem Cell Theory of Renewal, detailed in his book Cracking the Stem Cell Code.

Dr. Parolini obtained her Biology degree, graduating summa cum laude, from the University of Milan in 1988. In 1994 she completed her Doctorate in Cellular and Molecular Biotechnology in Biomedicine. She worked in the field of primary immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tennessee, USA (1991-1994) and at the University of Vienna, initially as visiting scientist (1995-1998), before being promoted to Lab Head (1998-2002). In 2002, Dr. Parolini was nominated Director of the E. Menni Research Center (CREM), Fondazione Poliambulanza, Brescia, Italy, where she has pioneered research on human placenta-derived stem cells. The main lines of research at CREM are centred around amniotic and chorionic membrane-derived cells and their conditioned media, with particular focus on immunomodulatory potential in vitro, as well as in vivo assessment of anti-fibrotic effects after transplantation/injection into preclinical animal models of induced fibrosis and autoimmune diseases. Dr. Parolini has been an invited speaker at over 80 international congresses and has been a scientific leader and organizer of several international events. She is the author of over 100 publications in peer-reviewed scientific journals as well as several book chapters, and has had one patent issued while two are currently pending. She is a member of several scientific societies and is the President of the International Placenta Stem Cell Society (IPLASS).

Shirwan, Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of Microbiology and Immunology and the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his graduate studies at the University of California in Santa Barbara, CA and postdoctoral studies at California Institute of Technology in Pasadena CA. He joined the University of Louisville in 1998 after holding academic appointments at various institutions in the United States. Shirwans research focuses on the modulation of immune system for the treatment of immune based diseases with particular focus on type 1 diabetes transplantation and development of vaccines against infections and cancer. Shirwan is widely published lectured at various National/International conferences served on various federal and nonprofit funding agencies and is on the Editorial Board of nine scientific journals He is a member of several National and International societies and the recipient of various awards.

Immunomodulation using proprietary novel recombinant proteins under clinically applicable protocols for therapeutic purposes with major focus on: Type 1 diabetes,Graft rejection,Bone marrow transplantation,Vaccines (cancer and infectious diseases)

Dr. Davis is a graduate of Harvard Medical School and had his postgraduate medical training at Albert Einstein College of Medicine and the NIH. His academic positions have included Chair, Department of Medicine, Albany Medical College. He has served as President, American Thyroid Association and as a member of the Board of Directors of the American Board of Internal Medicine. His scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He has co-authored more than 200 original research articles and 30 textbook chapters and he has edited three medical textbooks.

Dr. Davis directs a group of scientists who have defined molecular mechanisms for many nongenomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. They have described the cell surface receptor for thyroid hormone on integrin avb3 and the actions of tetraiodothyroacetic acid (tetrac) and reformulated (nanoparticulate) tetrac initiated at this plasma membrane receptor that are anti-angiogenic and anti-cancer by multiple cell surface and intracellular pathways.

Dr. Xiao is a Professor and the Director in School of Pharmaceutical Science at Dalian University of Technology China and the Functional Genomics and Proteomics Laboratories at the Creighton University School of Medicine, and an internationally recognized expert in the field of genomics and proteomics of cancer and bone disease. Dr. Xiao earns his Ph.D. in molecular biology in Institute of Biophysics at Chinese Academy of Sciences. He had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs, and cell cycle regulation. He has been regular reviewer or ad hoc reviewer for several medical journals, different funding agency and several journal Editorial Board members and senior Editors.

Vasiliki E. Kalodimou is Director of the Flow Cytometry-Research and Regenerative Medicine Department at IASO Maternity-Pediatric and Research Hospital in Athens, Greece. Before her current appointment, Kalodimou served as a haematology associate at General University Hospital of Heraklion, Crete, and as an instructor at both the General University Hospital of Heraklion and the Ipokratios Medical- Technical Institute of Athens. Kalodimou received her bachelor’s degree in Human Physiology and her master’s degree in Human Molecular Genetics from the Imperial College at the University of Medicine in London, UK. She completed her PhD at the University of Medicine in Athens, Greece, with an emphasis on stem cells and factors affecting their viability and absolute numbers.

Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine and Flow Cytometry. Also is working in the area of human genetics & population genetics. In collaboration with the Hellenic Flow Cytometry Society, Kalodimou has developed quality control schemes for stem cell marker enumeration. The goal of this work is to find helpful new applications for flow cytometry, evaluate the risk factors for stem cell infusion, and improve the clarity and accessibility of measurements by flow cytometry. Her work quantifies and ranks all risks of flow cytometry enumeration to prevent and minimize the false-positive results from different cytometer uses. She is also working to establish combinations of monoclonal antibodies for mesenchymal and adipose tissue stem cell enumeration. In addition to collaboration with state universities and pharmaceutical companies on research projects, Kalodimou frequently publishes her findings. The Greek edition of the book was published in 2010 and has been well-received while in 2013 the English edition of the book was puplished by AABB Press USA. She is a member of two subsections of the AABB Cellular Therapies Section and also an AABB assessor.

Dr. Mahin Khatami immigrated to USA in 1969 after training in Chemistry (BS) and Science Education (MS) in Iran. She received her MA in Biochemistry from SUNY at Buffalo (1977) and Ph.D. in Molecular Biology from the University Of Pennsylvania (UPA, 1980). Her Postdoctoral framings were in physiology, protein chemistry and immunology at UVA, Fox Chase Cancer Center & UPenn. She became A Faculty of Medicine at Dept. Ophthalmology-UPA until 1992; and in collaboration with a team of scientists, under direction and support of John H Rockey, MD, Ph.D., she quickly earned her supervisory responsibilities on two major projects; cell/molecular biology of diabetic retinopathy/maculopathy and experimental models of acute and chronic infl ammatory diseases. As a junior Faculty, she was perhaps a most productive scientist in the country as she published 39 scientifi c articles and over 60 abstracts in conference proceedings in the fi rst decade of her academic career. Since 1998, at NCI/NIH, extension of her earlier discoveries on immunobiology of infl ammatory diseases became closely relevant to her duties as Program Director-HAS for developing concepts for molecular diagnosis ,prevention and therapy of cancer for large clinical Trials ( Prostate-Long-Colorectal- Ovarian) and designs of cohort clinical studies. Dr. Khatami has lectured internationally; served as scientifi c judge; consultant to pharmaceutical companies; research advisor; member of professional societies; editorial member ships & reviewer activities; symposia organizer; president of graduate women In Science, Washington Chapter. Before retiring in 2009, her position title was Assistant Director for Technology Program Development, Offi ce of Technology and Industrial Relations and Program Director-IMAT, Offi ce of Director, NCI/NIH. She is currently Book Editor on Infl ammatory Diseases.

Mary MehrnooshEshaghian-Wilner has over 26 years of research experience in various areas within the field of Computer Engineering. Additionally, she has worked in the area of patent law for several years. She has published numerous scientific papers, including two books, and has handled the prosecution and infringement analysis of many complex U.S. and international patents. Eshaghian-Wilner currently is a Professor of Engineering Practice at the Electrical Engineering-Systems Department at the University of Southern California (USC), and since 2004 has been an Adjunct Professor of Electrical Engineering at the University of California, Los Angeles (UCLA). Prior to joining UCLA, she was a tenured full Professor and Department Head at the Computer Engineering Department of Rochester Institute of Technology. Professor Eshaghian-Wilner received her B.S. Degree in Biomedical and Electrical Engineering (1985), M.S. Degree in Computer Engineering (1985), her Engineers degree in Electrical Engineering (1988), and her Ph.D. in Computer Engineering (1988), all from USC. She holds a J.D. Degree from the Northwestern California School of Law, and has graduated Cum Laude with an LL.M. Degree from the Thomas Jefferson School of Law. She is admitted to the State Bar of California and the Washington, D.C. Bar, and is registered as a Patent Attorney with the United States Patent and Trademark Office.

Computing Architectures and Interconnects: Bio-inspired and Nanoscale Computing, MEMS, Optical Interconnects, VLSI and Reconfigurable chips.Computing Networks and Algorithms: Heterogeneous/Cluster/Grid/Cloud Computing, Mapping and Scheduling paradigms/algorithms/tools. Biomedical Applications: Nanomedicine, Bioinformatics, Sequence Alignment, Image-Processing, Computer Vision. Technology Law: Technology Transfer, Intellectual Property, Patent Reform, Digital Rights, Cyber Law/Crimes, Internet Privacy

Dr. Xinghua (Victor) Pan earned his Ph.D. degree with Dr. CC Tan and Z Geng from the Institute of Genetics, Fudan University School of Life Science, Shanghai, China. His thesis research was on the genetic associations between HLA and SLE and myasthenia gravis. He also obtained his M.D. degree (equivalent) from the Southern Medical University (previously called First Military Medical University), Guangzhou, China. Then he got his postdoctoral training at the National Key Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) with Dr. Min WU, identifying a candidate tumor suppressor gene with a grant support from the China Postdoctoral Science Foundation. Beginning in December 1994, he served as Associate Professor in Genetics in the Department of Biology, Second Military Medical University, Shanghai, China, where he earned a grant from the National Natural Science Foundation of China (NSFC), with which he established nm23 transgenic mouse and elucidated its effect on hepatocarcinoma. In addition, he studied EBV BHRF1 on nasopharyngeal carcinoma, reconstructed the phylogenetic tree for MHC genes. In 1997, Dr. Pan joined Dr. Sherman Weissman’s laboratory as a Postdoctoral Fellow in the Department of Genetics, Yale University School of Medicine, and developed an approach (GADAV) for unconditionally globally scanning of DNA mutations. From 2000 to 2004, he worked with Dr. Roger Lasken for Molecular Staging Inc. as a Research Scientist in Genomics Section and then Enzymology Leader, substantially contributed to the development of a kit for whole-genome-amplification (WGA), REPLIg, which is currently used world-wide and regarded as one of the best WGA technologies.

Dr. Pan’s main interest is functional genomics, focusing on the development and application of functional genomics technologies for analysis of single cells and low quantity of cells. These approaches include whole DNA pool amplification, whole mRNA transcriptome amplification, CpG methylation pattern scanning, DNase hypersensitive and resistant sites profiling, and telomere size analysis. Combining these technologies with second generation sequencing and microfluidic platform, and collaborating with other research teams, his group explores the genomic and epigenomic mechanism for reprogramming and transdifferentiation of human induced pluripotent stem cells (iPS), differentiation of embryo stem cells (ESCs) and adult stem cells (ASC, including hematopoietic stem cells, mesenchymal stem cells), molecular regulation underlying sensory neurons, embryo development and carcinogenesis and translational medicine.

Dr. Olexander L. Kukharchuk was specialized as “medical practioner” at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). CMSc. (Candidate of Medical Science) defended on 1989 in the session of specialized academy council at Kaunaski Medical Institute (Lithuania). D.M.Sc (Doctor of Medical Science) defended 1996 in the session of specialized academic council at Odessa Governmental Medical University (Ukraine). Associate Professor obtained on 1996, Professor obtained on 2001. 1982-1991: Assistant, Department of Pathophysiology Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1991-1994: Senior Tutor, Normal Physiology with course of Pathophysiology at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). Head of the Central Research Laboratory and Senior Tutor of the Pathophysiology Department at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1994- 1995: Head of Central Research Laboratory, Associate Professor of the Normal Physiology Department at Bucovinian Government Medical Academy (Ukraine, Chernivtsi). 1995-1997: Director of the Centre for Scientific-Medical Investigation at Bucovinian Government Medical Academy (Ukraine, Chernivtsi). 1997- 2002: Head of the Normal Physiology Department at Bucovinian Government Medical University (Ukraine, Chernivtsi). 2002-2005: Research Director of the Centre for Embryonic Cells “EmCell”(Ukraine, Kiev). 2005-2006: Research Director of the Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry (Ukraine, Kiev). 2006-2010: Director of Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry; Chief Specialist of the Ukraine Health Ministry by specialization “Transplantology”; Research Director of Institute of Cell Therapy (Ukraine, Kiev); Director EmProCell Clinical Research Pvt. Ltd. (India, Mumbai)

Physician/Scientist, and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer. Mutant BRCA1 and BRCA2 genes profiles in ovarian cancer. Proteomic profiling of metastatic genes of ovarian cancer. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

Apoptosis in cancer (hepatocellular carcinoma, lung cancer and thyroid cancer).

Margarita Glazova, received the Ph.D. (1997) fromSechenovInstitute of Evolutionary Physiology and Biochemistry, Russian Academy of Science and postdoctoral fellow of Adj. Professor P.Koskinen, Turku Centre for Biotechnology, University of Turku/Ã…boAkademi, Finland (2001-2003). She was a Research Associate of Prof. A.K.Murashov, East Carolina University Brody School of Medicine, Department of Physiology, Greenville, NC, USA (2004-2006). She is a Senior Researcher at the Laboratory of Comparative Somnology and Neuroendocrinology, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St.Petersburg, Russia. She has published more than 30 articles in peer-reviewed scientific journals